Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 8218 results

  1. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development Reference number: GID-TA11088 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]

    Awaiting development Reference number: GID-TA11377 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Galcanezumab for migraine [TSID10663]

    Awaiting development Reference number: GID-TA11311 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Deucravacitinib for treating active psoriatic arthritis [TSID11981]

    Awaiting development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development